Cantor Fitzgerald reissued their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a $28.00 price target on the biopharmaceutical company’s stock. Other equities analysts have also issued research reports about the stock. Royal Bank of Canada increased […]
Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) had its target price lifted by LADENBURG THALM/SH SH from $13.00 to $15.50 in a report issued on Wednesday morning, FlyOnTheWall reports. A number of other equities research analysts have also commented on MRNS. Oppenheimer lowered shares of Marinus Pharmaceuticals from an outperform rating to a market perform rating […]
Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Increased to $15 50 by Analysts at LADENBURG THALM/SH SH theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Raised to $21 00 at Royal Bank of Canada theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Altium Capital Management LP acquired a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 228,714 shares of the biopharmaceutical company’s stock, valued at approximately $1,578,000. Altium Capital Management LP owned about 0.45% of Marinus […]